Zevra Therapeutics Inc. (ZVRA), a commercial-stage company developing treatments for rare diseases, has announced financial results for the fourth quarter and full year that ended Dec.31, 2024.
The company's marketed drugs include OLPRUVA for the treatment of Urea Cycle Disorders, recently approved MIPLYFFA for the treatment of Niemann Pick disease type C, and *AZSTARYS for the treatment of Attention Deficit and Hyperactivity Disorder. *AZSTARYS is a partnered program with Commave Therapeutics.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.